UUDA.F Syntara Limited

Healthcare Drug Manufacturers - Specialty & Generic Frankfurt Exchange
0.0055 EUR
Close of Nov 12, 2026
0.0055 0.0285
Market cap
EUR 10.8M
P/E
-
P/B
2.16x
ROE
-55.5%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Jun 2026.

Is UUDA.F undervalued?

Graham number

The Graham number of Syntara Limited cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Syntara Limited fundamental analysis

No fundamental analysis for Syntara Limited yet.

Syntara Limited stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Syntara Limited

Syntara Limited, a clinical-stage drug development company, that targets extracellular matrix dysfunction through amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis in Australia. Its lead product candidate is amsulostat, which has completed Phase 2a clinical trial for the treatment of bone marrow cancer myelofibrosis, as well as in Phase 1c/2 clinical trial for patients with myelodysp…

Full company profile